Icon Plc (NASDAQ:ICLR) Shares Acquired by Farther Finance Advisors LLC

Farther Finance Advisors LLC grew its stake in Icon Plc (NASDAQ:ICLR) by 22.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 593 shares of the medical research company’s stock after buying an additional 110 shares during the quarter. Farther Finance Advisors LLC’s holdings in Icon were worth $99,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Private Trust Co. NA increased its stake in shares of Icon by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 82 shares in the last quarter. NBC Securities Inc. purchased a new position in shares of Icon in the 1st quarter valued at about $59,000. Horizon Investments LLC increased its stake in shares of Icon by 534.0% in the 4th quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 550 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its stake in shares of Icon by 128.2% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 1,166 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 655 shares in the last quarter. Finally, Captrust Financial Advisors increased its stake in shares of Icon by 2.0% in the 4th quarter. Captrust Financial Advisors now owns 35,301 shares of the medical research company’s stock valued at $7,403,000 after purchasing an additional 701 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

ICLR has been the subject of several recent analyst reports. JPMorgan Chase & Co. lowered Icon from an “overweight” rating to a “neutral” rating and cut their price target for the company from $265.00 to $150.00 in a research note on Tuesday, April 29th. Robert W. Baird cut their price target on Icon from $192.00 to $160.00 and set a “neutral” rating for the company in a research note on Friday, May 2nd. Citigroup cut their price target on Icon from $290.00 to $215.00 and set a “buy” rating for the company in a research note on Monday, April 7th. Truist Financial cut their price target on Icon from $262.00 to $208.00 and set a “buy” rating for the company in a research note on Thursday, April 10th. Finally, Barclays cut their price objective on Icon from $165.00 to $155.00 and set an “equal weight” rating for the company in a research note on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Icon has a consensus rating of “Moderate Buy” and a consensus target price of $213.08.

Icon Trading Up 2.0%

Shares of Icon stock opened at $146.48 on Friday. The stock has a market cap of $11.83 billion, a P/E ratio of 15.96, a P/E/G ratio of 1.53 and a beta of 1.15. The stock’s 50 day simple moving average is $138.75 and its 200-day simple moving average is $174.08. Icon Plc has a 1-year low of $125.10 and a 1-year high of $347.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.27 and a quick ratio of 1.27.

Icon (NASDAQ:ICLR) last issued its earnings results on Wednesday, April 30th. The medical research company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.17 by $0.02. The business had revenue of $2 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Icon had a return on equity of 11.46% and a net margin of 9.25%. The business’s revenue for the quarter was down 4.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.47 EPS. Analysts predict that Icon Plc will post 13.38 EPS for the current fiscal year.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.